“Polyrizon Takes a Heartfelt Step Towards its 2025 Clinical Trial: GMP Manufacturing and Preliminary Process for PL-14 Allergy Blocker Commences”
Eurofins CDMO Amatsiaquitaine S.A.S. to Support Polyrizon in Future Commercialization Efforts Raanana, Israel, Jan. 23, 2025 (GLOBE NEWSWIRE) — Polyrizon Ltd. Exciting news has emerged from the pharmaceutical industry as Eurofins CDMO Amatsiaquitaine S.A.S. announces its collaboration with Polyrizon in future commercialization efforts. This partnership holds significant promise for both companies as they work towards…